Compounds > corynoxine
Page last updated: 2024-11-12

corynoxine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

corynoxine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10475115
CHEMBL ID1909424
CHEBI ID70072
MeSH IDM000609156

Synonyms (21)

Synonym
CHEMBL1909424
chebi:70072 ,
corynoxine
S9027
CS-3802
6877-32-3
AC-34387
Q-100772
HY-N0901
methyl (e)-2-[(3s,6's,7's,8'as)-6'-ethyl-2-oxospiro[1h-indole-3,1'-3,5,6,7,8,8a-hexahydro-2h-indolizine]-7'-yl]-3-methoxyprop-2-enoate
AKOS032948990
Q27138410
corynoxine a
ZB1866
(e)-methyl 2-((1's,6's,7's,8a's)-6'-ethyl-2-oxo-3',5',6',7',8',8a'-hexahydro-2'h-spiro[indoline-3,1'-indolizin]-7'-yl)-3-methoxyacrylate
CCG-268458
methyl (e)-2-((3s,6's,7's,8a's)-6'-ethyl-2-oxo-2',3',6',7',8',8a'-hexahydro-5'h-spiro[indoline-3,1'-indolizin]-7'-yl)-3-methoxyacrylate
1443767-78-9
DTXSID201318329
AS-78371
bdbm50566312
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
indolizines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Mu-type opioid receptorHomo sapiens (human)Ki0.01640.00000.419710.0000AID1749821
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (16)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID1775280Stability of the compound in rat plasma assessed as proportion of compound deviation from nominal concentration at 2.5 ng/ml measured under freeze-thaw conditions for 3 cycles by UPLC-MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1775279Stability of the compound in rat plasma assessed as proportion of compound deviation from nominal concentration at 160 ng/ml measured in autosampler for 24 hrs by UPLC-MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1749816Displacement of [3H]DADLE from human recombinant delta opioid receptor expressed in Chem-1 (RBL) cells at 10000 nM incubated for 60 mins by radiometric scintillation analysis
AID1775341Stability of the compound in rat plasma assessed as drug recovery2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID568585Cytotoxicity against human HL60 cells after 48 hrs by MTT assay2011Journal of natural products, Jan-28, Volume: 74, Issue:1
Macrophyllionium and macrophyllines A and B, oxindole alkaloids from Uncaria macrophylla.
AID1775278Stability of the compound in rat plasma assessed as proportion of compound deviation from nominal concentration at 2.5 ng/ml measured in autosampler for 24 hrs by UPLC-MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1749817Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in Chem-1 (RBL) cells at 100 nM incubated for 60 mins by radiometric scintillation analysis
AID568587Vasodilatory activity in Sprague-Dawley rat thoracic aorta smooth muscle assessed as inhibition of phenylephrine-induced vasoconstriction2011Journal of natural products, Jan-28, Volume: 74, Issue:1
Macrophyllionium and macrophyllines A and B, oxindole alkaloids from Uncaria macrophylla.
AID568586Cytotoxicity against human SW480 cells after 48 hrs by MTT assay2011Journal of natural products, Jan-28, Volume: 74, Issue:1
Macrophyllionium and macrophyllines A and B, oxindole alkaloids from Uncaria macrophylla.
AID1749818Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in Chem-1 (RBL) cells at 10000 nM incubated for 60 mins by radiometric scintillation analysis
AID1775283Stability of the compound in rat plasma assessed as proportion of compound deviation from nominal concentration at 160 ng/ml measured at -80 degC for 4 weeks by UPLC-MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1775342Stability of the compound in water-methanol mixture (1:1) assessed as drug recovery2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1385452Cytotoxicity against human HepG2 cells assessed as reduction in cell viability at 100 uM after 24 hrs by MTT assay2018Journal of natural products, 08-24, Volume: 81, Issue:8
Alkaloids with Immunosuppressive Activity from the Bark of Pausinystalia yohimbe.
AID1385454Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 100 uM after 24 hrs by MTT assay2018Journal of natural products, 08-24, Volume: 81, Issue:8
Alkaloids with Immunosuppressive Activity from the Bark of Pausinystalia yohimbe.
AID1385451Cytotoxicity against human MCF7 cells assessed as reduction in cell viability at 100 uM after 24 hrs by MTT assay2018Journal of natural products, 08-24, Volume: 81, Issue:8
Alkaloids with Immunosuppressive Activity from the Bark of Pausinystalia yohimbe.
AID568588Vasodilatory activity in Sprague-Dawley rat thoracic aorta smooth muscle assessed as inhibition of KCL-induced vasoconstriction2011Journal of natural products, Jan-28, Volume: 74, Issue:1
Macrophyllionium and macrophyllines A and B, oxindole alkaloids from Uncaria macrophylla.
AID1775277Stability of the compound in rat plasma assessed as proportion of compound deviation from nominal concentration at 160 ng/ml measured on the bench-top for 2 hrs by UPLC-MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1749822Antinociceptive activity in iv dosed Sprague-Dawley rat assessed as hot plate latency compound administered as cumulative dose at 5 mins intervals by Hot-plate test
AID1749815Displacement of [3H]DADLE from human recombinant delta opioid receptor expressed in Chem-1 (RBL) cells at 100 nM incubated for 60 mins by radiometric scintillation analysis
AID1385453Cytotoxicity against human HT-29 cells assessed as reduction in cell viability at 100 uM after 24 hrs by MTT assay2018Journal of natural products, 08-24, Volume: 81, Issue:8
Alkaloids with Immunosuppressive Activity from the Bark of Pausinystalia yohimbe.
AID1749819Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in HEK293 cells at 100 nM incubated for 120 mins by radiometric scintillation analysis
AID1749821Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in HEK293 cells incubated for 120 mins by radiometric scintillation analysis
AID1775275Stability of the compound in rat plasma assessed as proportion of compound deviation from nominal concentration at 2.5 ng/ml measured on the bench-top for 2 hrs by UPLC-MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1775281Stability of the compound in rat plasma assessed as proportion of compound deviation from nominal concentration at 160 ng/ml measured under freeze-thaw conditions for 3 cycles by UPLC-MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1775282Stability of the compound in rat plasma assessed as proportion of compound deviation from nominal concentration at 2.5 ng/ml measured at -80 degC for 4 weeks by UPLC-MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1749820Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in HEK293 cells at 10000 nM incubated for 120 mins by radiometric scintillation analysis
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (55.56)24.3611
2020's4 (44.44)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.29 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index34.57 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
hydrogen
Hydrogen: The first chemical element in the periodic table with atomic symbol H, and atomic number 1. Protium (atomic weight 1) is by far the most common hydrogen isotope. Hydrogen also exists as the stable isotope DEUTERIUM (atomic weight 2) and the radioactive isotope TRITIUM (atomic weight 3). Hydrogen forms into a diatomic molecule at room temperature and appears as a highly flammable colorless and odorless gas.. dihydrogen : An elemental molecule consisting of two hydrogens joined by a single bond.		7.110elemental hydrogen;
elemental molecule;
gas molecular entity		antioxidant;
electron donor;
food packaging gas;
fuel;
human metabolite
verapamil
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.		2.0610aromatic ether;
nitrile;
polyether;
tertiary amino compound
corynanthine
Corynanthine: A stereoisomer of yohimbine.		2.1710yohimban alkaloid
mitraphylline
mitraphylline: isolated from Uncaria tomentosa		2.3110indolizines
2-oxindole
2-oxindole: RN given refers to parent cpd; structure. indolin-2-one : An indolinone carrying an oxo group at position 2.		2.110gamma-lactam;
indolinone
hirsutine, (16e,20beta)-isomer
[no description available]		2.6320alkaloidmetabolite
mitragynine
[no description available]		2.3110monoterpenoid indole alkaloid
isorhyncophylline
[no description available]		2.0610indolizinesmetabolite
paynantheine
paynantheine: structure in first source		2.3110
hirsutine
[no description available]		2.3110
Rhynchophylline
[no description available]		2.0610indolizinesmetabolite
raubasine
raubasine: RN given refers to (19alpha)-isomer; structure		2.3110yohimban alkaloid
corynoxine b
corynoxine B: structure in first source		3.3960indolizinesmetabolite
alpha-synuclein
alpha-Synuclein: A synuclein that is a major component of LEWY BODIES and plays a role in SYNUCLEINOPATHIES, neurodegeneration and neuroprotection.		2.1510
mitragynine, (3beta,16e,20beta)-isomer
[no description available]		2.3110
mitragynine
speciogynine: structure in first source		2.3110
7-hydroxymitragynine
7-hydroxymitragynine: an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa; structure in first source		2.3110alkaloid
corynoxeine
corynoxeine: active principles of Uncariae Ramulus et Uncus; structure given in first source for ((7beta,16E,20alpha)-isomer) and ((16E,20alpha)-isomer); RN given refers to ((7beta,16E,20alpha)-isomer)		2.1710
ConditionIndicatedRelationship StrengthStudiesTrials
Acute Confusional Senile Dementia
[description not available]		02.8220
Alzheimer Disease
A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)		02.8220
Degenerative Diseases, Central Nervous System
[description not available]		02.1510
Neurodegenerative Diseases
Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.		02.1510